Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MESO

Mesoblast Ltd ADR

Sep 12 • 04:00PM ET

14.82

-0.55 -3.58 %

Healthcare • Biotechnology • Australia • NASD

Peers: BMRN SRPT IONS SGMO BLUE ALNY FATE TVRD CYTK KPTI

| Held by: IBB APIE IBBQ BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.85	Insider Own	-	Shs Outstand	127.99M	Perf Week	2.99%
Market Cap	1.90B	Forward P/E	79.13	EPS next Y	0.19	Insider Trans	-	Shs Float	127.74M	Perf Month	-2.44%
Enterprise Value	1.86B	PEG	-	EPS next Q	-	Inst Own	2.64%	Short Float	1.89%	Perf Quarter	21.88%
Income	-102.16M	P/S	110.28	EPS this Y	60.60%	Inst Trans	-15.02%	Short Ratio	10.08	Perf Half Y	11.60%
Sales	17.20M	P/B	3.17	EPS next Y	156.19%	ROA	-14.05%	Short Interest	2.42M	Perf YTD	-25.15%
Book/sh	4.67	P/C	11.74	EPS next 5Y	-	ROE	-18.96%	52W High	22.00 -32.64%	Perf Year	142.95%
Cash/sh	1.26	P/FCF	-	EPS past 3/5Y	14.16% 9.59%	ROIC	-15.28%	52W Low	6.00 147.00%	Perf 3Y	168.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	18.91% -11.49%	Gross Margin	32.93%	Volatility	3.26% 3.17%	Perf 5Y	-54.98%
Dividend TTM	-	EV/Sales	108.34	EPS Y/Y TTM	4.89%	Oper. Margin	-363.56%	ATR (14)	0.69	Perf 10Y	-51.73%
Dividend Ex-Date	-	Quick Ratio	1.77	Sales Y/Y TTM	192.01%	Profit Margin	-593.86%	RSI (14)	50.33	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	1.99	EPS Q/Q	10.96%	SMA20	-1.24%	Beta	2.30	Target Price	24.23
Payout	-	Debt/Eq	0.21	Sales Q/Q	-3.91%	SMA50	2.84%	Rel Volume	0.77	Prev Close	15.37
Employees	81	LT Debt/Eq	0.12	Earnings	Aug 28 AMC	SMA200	7.37%	Avg Volume	239.65K	Price	14.82
IPO	Jan 18, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	-14.30% -0.49%	Trades		Volume	185,409	Change	-3.58%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-18-25	Downgrade	Jefferies	Buy → Hold
Dec-23-24	Downgrade	Jefferies	Buy → Hold
Sep-24-24	Upgrade	Maxim Group	Hold → Buy	$12
Aug-29-24	Upgrade	Jefferies	Hold → Buy
Jul-23-24	Upgrade	Piper Sandler	Neutral → Overweight	$4 → $11
Aug-31-23	Upgrade	Jefferies	Hold → Buy
Aug-07-23	Downgrade	Maxim Group	Buy → Hold
Aug-04-23	Downgrade	William Blair	Outperform → Mkt Perform
Aug-04-23	Downgrade	Piper Sandler	Overweight → Neutral	$7 → $2
Mar-09-23	Initiated	William Blair	Outperform	$8
Dec-06-22	Downgrade	Jefferies	Buy → Hold
Sep-06-22	Initiated	Piper Sandler	Overweight	$7
Apr-07-21	Upgrade	Maxim Group	Hold → Buy	$18
Dec-22-20	Downgrade	Maxim Group	Buy → Hold
Dec-04-20	Downgrade	Chardan Capital Markets	Neutral → Sell	$7.50
Oct-22-20	Initiated	RBC Capital Mkts	Sector Perform	$12
Aug-14-20	Reiterated	Maxim Group	Buy	$16 → $22
May-28-20	Reiterated	H.C. Wainwright	Buy	$14 → $21
Jan-31-19	Resumed	H.C. Wainwright	Buy	$6.50
Mar-22-18	Downgrade	Credit Suisse	Neutral → Underperform

Show Previous Ratings

Sep-03-25 09:47PM	Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes (GlobeNewswire)
Aug-28-25 08:24PM	Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil (GlobeNewswire) -13.29%
Aug-27-25 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Aug-17-25 01:51AM	Canaccord Genuity Initiates Coverage of Mesoblast Limited (MESO) with Buy Rating (Insider Monkey)
Jul-28-25 10:08AM	Mesoblast Limited (MESO) Launches First Cell Therapy for Children (Insider Monkey)
12:00PM	Loading…
Jul-22-25 12:00PM	Mesoblast Limited (MESO) Is Up 40.59% in One Week: What You Should Know (Zacks)
Jul-17-25 08:38PM	Successful Commercial Launch of Ryoncil (GlobeNewswire) +8.72% +26.58%
Jun-30-25 08:36PM	Mesoblast and FDA Align on Key Items for Revascor Biologic License Application in Ischemic Heart Failure (GlobeNewswire) +11.29%
Jun-29-25 01:28PM	Mesoblast (MESO) Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for Ryoncil (Insider Monkey)
Jun-11-25 09:24PM	Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor in Ischemic Heart Failure and Label Extension for Ryoncil in Adults With GvHD (GlobeNewswire) -6.61%
May-27-25 09:14AM	Which S&P 500 Move Matters? (Motley Fool)
May-14-25 10:57PM	FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil (GlobeNewswire)
May-05-25 02:44AM	Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials (Seeking Alpha) -6.22%
Apr-29-25 08:53PM	Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025 (GlobeNewswire)
Apr-28-25 07:44PM	Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board (GlobeNewswire)
09:20PM	Loading…
Apr-16-25 09:20PM	Mesoblast Extends Payer Coverage For Ryoncil to Over 100 Million US Lives (GlobeNewswire)
Apr-07-25 09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
Apr-03-25 06:58PM	Mesoblast Allogeneic Cell Therapy Products Are Designated 'U.S. Country of Origin' and Not Subject to U.S. Tariffs (GlobeNewswire) -8.88%
Apr-02-25 07:15PM	Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor in Ischemic Heart Failure (GlobeNewswire)
Mar-30-25 07:39PM	First Three Children to Commence Treatment With Ryoncil (GlobeNewswire)
Mar-26-25 08:19PM	Ryoncil is Now Available for Purchase in the United States (GlobeNewswire)
Mar-13-25 07:42PM	Ryoncil Product Information Now Available in All Four Major Drug Pricing Compendia in United States (GlobeNewswire)
Mar-12-25 07:30AM	Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall (GlobeNewswire)
Mar-06-25 06:54PM	Mesoblast Added to S&P/ASX 200 INDEX (GlobeNewswire) -7.69%
Feb-26-25 05:30PM	Mesoblast Sets Ryoncil Price Based on Economic Value of Treatment With Planned Product Availability This Quarter (GlobeNewswire)
Feb-25-25 06:13PM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Feb-23-25 06:33PM	Dr. Gregory George MD PhD Joins Mesoblast Board (GlobeNewswire)
Feb-19-25 06:00AM	Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now (GlobeNewswire)
Feb-13-25 06:37PM	Ryoncil FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings (GlobeNewswire)
Jan-30-25 07:11PM	Ryoncil Commercial Launch Update and Product Pipeline (GlobeNewswire)
06:20PM	Loading…
06:20PM	Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 (GlobeNewswire)
Dec-19-24 04:21PM	Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval (Investor's Business Daily) +36.82% -12.71%
Dec-18-24 07:08PM	Mesoblast's RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy (GlobeNewswire)
07:30AM	Mesoblast to be Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-05-24 06:29AM	Mesoblasts Revascor Therapy Shows Promise in Heart Failure (TipRanks)
Dec-04-24 06:32PM	FDA Grants Revascor (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease (GlobeNewswire)
Dec-02-24 06:20PM	Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation (GlobeNewswire)
Nov-14-24 06:37AM	Mesoblast Issues 2 Million Warrants for Strategic Flexibility (TipRanks)
Oct-30-24 07:11PM	Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024 (GlobeNewswire)
Oct-19-24 06:30AM	Mesoblast Advances Cellular Medicines Amid FDA Hopes (TipRanks)
Sep-29-24 08:55PM	Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch (GlobeNewswire)
Aug-31-24 05:14PM	10 Best Australian Stocks To Buy According to Hedge Funds (Insider Monkey)
Aug-28-24 07:27PM	Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024 (GlobeNewswire)
Aug-27-24 07:25PM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Jul-30-24 09:13PM	Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024 (GlobeNewswire)
Jul-23-24 07:53AM	FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) (GlobeNewswire) +9.54%
Jul-21-24 08:45PM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain (GlobeNewswire)
Jul-08-24 08:37PM	Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) (GlobeNewswire)
Jul-02-24 08:04AM	Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates (Zacks)
Jul-01-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
01:55AM	Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week (GlobeNewswire)
Jun-02-24 08:23PM	Mesoblast Corporate Presentation at Investor Conference (GlobeNewswire)
Apr-29-24 09:05PM	Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024 (GlobeNewswire) +13.78% -7.04%
Mar-30-24 11:49AM	10 Best Long Term ASX Stocks To Invest In (Insider Monkey)
Mar-27-24 11:00AM	Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up (Zacks) -11.20%
Mar-25-24 10:34PM	United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) (GlobeNewswire) +78.64%
Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Mar-13-24 07:30PM	Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer (GlobeNewswire) -8.27%
Mar-10-24 07:54PM	United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) (GlobeNewswire)
Mar-03-24 08:25AM	Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript (Insider Monkey)
Feb-28-24 05:57PM	Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 (GlobeNewswire) -5.74%
Feb-26-24 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Feb-14-24 07:46PM	United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease (GlobeNewswire) +5.96%
Jan-30-24 09:13PM	Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023 (GlobeNewswire)
Jan-19-24 11:30AM	Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug (Zacks) +11.63%
Jan-18-24 06:36PM	United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease (GlobeNewswire)
Nov-27-23 07:28AM	Mesoblast files applications with US FDA for HLHS therapy (Pharmaceutical Business Review)
Nov-26-23 06:56PM	Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease (GlobeNewswire)
Nov-21-23 06:32PM	Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD (GlobeNewswire) +10.74%
Oct-30-23 08:04PM	Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023 (GlobeNewswire) +5.98%
Sep-26-23 06:18AM	Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee (GlobeNewswire)
Sep-22-23 04:59PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Sep-21-23 03:30AM	Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval (GlobeNewswire)
Aug-30-23 07:07PM	Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023 (GlobeNewswire) +12.59%
Aug-29-23 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Aug-04-23 09:38AM	Apple downgraded, Amazon upgraded: Wall Street's top analyst calls (The Fly) -58.90%
Aug-03-23 08:10PM	Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children (GlobeNewswire)
Jul-30-23 08:31PM	Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023 (GlobeNewswire)
Jun-04-23 08:21PM	Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role (GlobeNewswire)
May-25-23 07:28PM	Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023 (GlobeNewswire) +5.22%
May-24-23 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Apr-27-23 09:00PM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Apr-25-23 08:47PM	Mesoblast Completes Private Placement (GlobeNewswire)
Mar-21-23 09:20PM	FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing (GlobeNewswire)
Mar-07-23 07:03PM	FDA Accepts Mesoblasts Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023 (GlobeNewswire) -5.90% +23.76%
Feb-27-23 05:13PM	Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022 (GlobeNewswire)
04:49PM	DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC) (GlobeNewswire)
Feb-26-23 07:38PM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Feb-16-23 06:16PM	Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting of Transplantation Research and Therapy (GlobeNewswire) -7.82%
Feb-08-23 06:09PM	FDA Grants Regenerative Medicine Advanced Therapy (Rmat) Designation for Rexlemestrocel-L in Chronic Low Back Pain (GlobeNewswire)
Jan-31-23 06:30PM	Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD) (GlobeNewswire) +8.79%
04:40AM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Dec-22-22 07:18PM	Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility (GlobeNewswire)
Dec-15-22 12:00PM	Mesoblast Limited (MESO) Upgraded to Buy: Here's What You Should Know (Zacks) -5.15%
Dec-02-22 03:13PM	Mesoblast Limited's (ASX:MSB) Shift From Loss To Profit (Simply Wall St.)
Nov-23-22 09:38AM	Mesoblast Lead Product Shows Durable Long-Term Survival At Four Years In Kids With Graft Versus Host Disease (Benzinga)
Nov-22-22 06:32PM	Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) (GlobeNewswire)
06:01PM	Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022 (GlobeNewswire)
Nov-21-22 06:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire) +5.50%
Oct-30-22 07:50PM	Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022 (GlobeNewswire)

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MESO

Mesoblast Ltd ADR

Upgrade your FINVIZ experience